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ABSTRACT
HIV/AIDS continues to be an important public health challenge in sub Saharan Africa. 
It is estimated that approximately 68% of people living with HIV in the world are from 
this region [1].  South Africa has the largest infected population in the world, the adult 
(15-49 years) HIV prevalence is estimated at 17.64% [2].  It has been estimated that 
40 - 70% of such HIV positive individuals present with head and neck manifestations, 
which include infection, inflammation and tumours, and are often the only and initial 
presenting sign [3,4].  Peritonsillar abscess is the most common deep infection of the 
head and neck in young adults and can occur in all age groups, but the highest 
incidence is in adults 20 to 40 years of age [5].
The aim of this study was to assess the relationship between peritonsillar abscess 
and the HIV status of patients. Method: An analytical cross sectional study utilising 
retrospective clinical data from ward registers, patient records, treatment registers 
and National Health Laboratory System (NHLS) databases.  This study was 
conducted in the adult ENT ward at the Chris Hani Baragwanath Hospital and sample 
consisted of patient records over a 4 year period from January 2005 to December 
2008. All patients admitted to the ENT ward with the discharge diagnosis of 
peritonsillar abscess that have been tested for HIV were included in this study.
In this study period 450 patient files were reviewed of which 291 fulfilled the inclusion 
criteria.  The demographic details, clinical presentation which included head and 
neck manifestations of HIV, the HIV status, management and complications of 
peritonsillar abscess were recorded.  This data was analysed using STATA-10 
software. 
III
Results:  The age ranged from 15 to 63 years with a mean (SD) 29.3 years (9.58). 
From the 291 patients, 86 (29.55%) were HIV positive.  This is significantly higher 
than the adult (15-49years) HIV prevalence rate of 17.64% [6].  The male: female 
ratio of HIV positive patients 1:1.53.  Forty-nine (16.84%) patients presented with 
cervical lymph nodes of which 65.31% were HIV positive (P< 0.001).  From the 86 
HIV positive patients oral candida was present in 15.12% (P<0.001), lymphoma in 
6.98% (P<0.001), oral hairy leukoplakia in 2.33%, Kaposi’s sarcoma in 1.16% and 
complications (parapharyngeal abscess) 3.48%.  There was no statistical 
significance in the management of HIV positive patients, however hospital stay was 
longer with a mean of 3.802 days (P<0.001).  
From this study sample the HIV prevalence of 29.55% suggests that peritonsillar 
abscess may be an early clinical marker of HIV infection. Due to the high incidence of 
head and neck manifestations in HIV positive patients identifying a clinical marker 
(quinsy) in the earlier stages of HIV infection would allow for better screening, earlier 
diagnosis and treatment of HIV infection. 
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CHAPTER 1 – INTRODUCTION 
 
1.0 General Remarks 
 
HIV/AIDS continues to be an important public health challenge in sub Saharan Africa.  It 
is estimated that approximately 68% of people living with HIV in the world are from this 
region [1].  South Africa has the largest infected population in the world, the adult  
(15-49 years) HIV prevalence is estimated at 17.64% [2].  It has been estimated that  
40 - 70% of such HIV positive individuals present with head and neck manifestations, 
which include infection, inflammation and tumours, and are often the only and initial 
presenting sign [3,4]. 
 
The otorhinolaryngological abnormalities in HIV patients have been reported, but the 
literature is lacking a description of their occurrence during the earlier stages of the HIV 
infection.  Peritonsillar abscess is the most common deep infection of the head and neck 
in young adults, despite the widespread and early use of antibiotics for treating tonsillitis 
and pharyngitis.  Peritonsillar abscess can occur in all age groups, but the highest 
incidence is in adults 20 to 40 years of age [5].  Peritonsillar abscesses are almost 
always first encountered by the family physician or primary health care clinics, and those 
with appropriate training and experience can diagnose and treat most patients. Prompt 
recognition and initiation of therapy is important to avoid potential serious complications. 
 
The aim of this project is to assess the relationship between peritonsillar abscess and 
the HIV status of patients, with regards to clinical presentation and management.  The 
study was conducted at the Chris Hani Baragwanath Hospital.  This hospital, with its 
2888 beds, is the largest acute care hospital in the world. It is situated to the south west 
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of Johannesburg, on the southern border of Soweto. The Hospital grounds cover an 
area of 173 acres, consisting of 429 buildings with a total floor area of 233 785 m².   
The hospital has a staff establishment of nearly 5000, of which approximately 600 are 
doctors and 2 000 are nurses.  It is the only public hospital serving ±3,5 million people in 
Soweto and provides half of all the hospital services in Southern and Western 
Gauteng[7]. 
 
 
1.1 Review of literature 
 
1.1.1 Prevalence of HIV  
 
The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health 
Organization (WHO), estimated the number of people living with HIV at the end of 2007 
to be 39.5 million worldwide [1].  While approximately 10% of the world’s population lives 
in sub-Saharan Africa, an enormous 64% of all people living with HIV live in this region 
including 77% of all women living with HIV.   
 
Levels of infection vary throughout this region with countries north and west having adult 
(15-49) prevalence levels of between 1% and 5%, while Southern Africa have 
prevalence levels of between 10-20%. HIV prevalence has declined in some countries, 
Uganda in the early 1990s, and recently Zimbabwe, Kenya and urban areas of Burkina 
Faso. These declines seem to be linked to changes in key sexual behaviors [8].  Overall, 
HIV prevalence in this region appears to be leveling off, albeit at high levels [Figure 1.1]. 
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Figure 1.1 Estimated numbers of people living with HIV and adult HIV 
prevalence. Global HIV epidemic, 1990–2007; and, HIV epidemic in 
Sub-Saharan Africa, 1990–2007 
 
 
 
HIV and AIDS is one of the major challenges facing South Africa today. Some two 
decades since the introduction of this disease in the general population, the 
epidemiological situation is characterized by very large numbers of people living with 
HIV and a disproportionate effect on particular sectors of society, young women, the 
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poor, as well as those living in underdeveloped areas in the country. HIV and AIDS, 
however affects the lives of all people who live in South Africa in different ways [9]. 
 
The national HIV prevalence rates have been stable for several years and there is now 
evidence of the epidemic being on the decline. The 2007 national antenatal HIV 
prevalence stands at 28.0%.  This represents a possible 1.1% reduction in HIV 
prevalence from 2006 to 2007 [6]. When the 2005 and 2007 HIV estimates are 
compared, we observe a statistically significant decline in HIV  
prevalence [Figure 1.2]. 
 
 
 
 
 
Figure 1.2 National HIV prevalence trends among antenatal clinic attendees,  
South Africa, 1990 to 2007. 
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Although the provincial HIV prevalence estimates among antenatal clinic attendees 
showed that there was a decline in the Gauteng province the prevalence still remains the 
fourth highest in South Africa [6].  The distribution of HIV by province is shown 
 in [table 1.1] 
 
 
 
Table 1.1 Provincial HIV prevalence estimates among antenatal clinic 
attendees, South Africa, 2005 – 2007. 
 
 
 
 
 
 
The HIV prevalence estimate in older age groups (30 – 34 years and 35 – 39 years) is of 
concern as it remains at similar levels with a tendency towards an increase. The HIV 
prevalence has significantly increased in these specific age groups, from 37.0% in 2006 
to 40.2% in 2007 and 29.30% in 2006 to 33.2% in 2007 respectively [Table 1.2].   
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The decline in the age group (15-19years) particularly, implies a reduction in new 
infections (incidence) in the general population [10]. 
 
 
Table 1.2 National HIV prevalence estimates by age group among antenatal 
clinic attendees, South Africa, 2005 – 2007. 
 
 
 
 
Antenatal surveys are not designed to provide information on HIV prevalence in the 
overall population (men, non-pregnant women and even children).  These estimates are 
derived using mathematical models on the basis of antenatal survey data. The UNAIDS 
Spectrum model (UNAIDS, 2002) has been used.  The number of people who are 
estimated to have HIV infection is approximately 5.27 million. The HIV prevalence 
amongst adults 15-49 years is estimated at 17.64% [2].  
 
1.1.2 Classification of HIV 
HIV disease staging and classification systems are critical tools for tracking and 
monitoring the HIV epidemic and for providing clinicians and patients with important 
information about HIV disease stage and clinical management. Two major classification 
systems currently are in use: the U.S. Centers for Disease Control and Prevention 
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(CDC) classification system and the World Health Organization (WHO) Clinical Staging 
and Disease Classification System [11]. 
 
The WHO clinical staging system for HIV/ AIDS was developed in 1990 and emphasized 
the use of clinical parameters to guide clinical decision-making for the management of 
HIV/AIDS patients.  It was designed for use in resource-limited settings such as limited 
access to laboratory services. The WHO clinical staging system has been widely used in 
resource-limited countries, particularly in the African Region, and has proved pragmatic 
and useful in facilities at both the first and referral level [12]. 
 
In contrast to the WHO system, the CDC disease staging system assesses the severity 
of HIV disease by CD4 cell counts and by the presence of specific HIV-related 
conditions. The definition of AIDS includes all HIV-infected individuals with CD4 counts 
of <200 cells/µL (or CD4 percentage <14%) as well as those with certain HIV-related 
conditions and symptoms. Although the fine points of the classification system rarely are 
used in the routine clinical management of HIV-infected patients, a working knowledge 
of the staging criteria (in particular the definition of AIDS) is useful in patient care. In 
addition, the CDC system is used in clinical and epidemiologic research [11].  
 
In response to the changing landscape of HIV/AIDS, particularly in resource-limited 
settings, and specifically to support scale up of anti-retroviral treatment, revisions  
and harmonization of the clinical staging and case definitions for surveillance are 
required [12]. The WHO clinical staging of HIV/AIDS is universally used in South Africa 
and presented in summary [table 1.3] 
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Table 1.3 WHO Clinical Staging of HIV/AIDS for Adults and Adolescents 
 
Primary HIV Infection 
• Asymptomatic  
• Acute retroviral syndrome 
Clinical Stage 1 
• Asymptomatic  
• Persistent generalized lymphadenopathy 
Clinical Stage 2 
• Moderate unexplained weight loss (<10% of presumed or measured body weight)  
• Recurrent respiratory infections (sinusitis, tonsillitis, otitis media, and pharyngitis)  
• Herpes zoster  
• Angular cheilitis  
• Recurrent oral ulceration  
• Papular pruritic eruptions  
• Seborrheic dermatitis  
• Fungal nail infections 
Clinical Stage 3 
• Unexplained severe weight loss (>10% of presumed or measured body weight)  
• Unexplained chronic diarrhea for >1 month  
• Unexplained persistent fever for >1 month (>37.6°C, intermittent or constant)  
• Persistent oral candidiasis (thrush)  
• Oral hairy leukoplakia  
• Pulmonary tuberculosis (current)  
• Severe presumed bacterial infections (eg, pneumonia, empyema, pyomyositis, bone 
or joint infection, meningitis, bacteremia)  
• Acute necrotizing ulcerative stomatitis, gingivitis, or periodontitis  
• Unexplained anemia (hemoglobin <8 g/dL)  
• Neutropenia (neutrophils <500 cells/µL)  
• Chronic thrombocytopenia (platelets <50,000 cells/µL) 
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Table 1.3 WHO Clinical Staging of HIV/AIDS for Adults and Adolescents continued. 
Clinical Stage 4 
• HIV wasting syndrome, as defined by the CDC (see Table 3, above)  
• Pneumocystis pneumonia  
• Recurrent severe bacterial pneumonia  
• Chronic herpes simplex infection (orolabial, genital, or anorectal site for >1 month or 
visceral herpes at any site)  
• Esophageal candidiasis (or candidiasis of trachea, bronchi, or lungs)  
• Extrapulmonary tuberculosis  
• Kaposi sarcoma  
• Cytomegalovirus infection (retinitis or infection of other organs)  
• Central nervous system toxoplasmosis  
• HIV encephalopathy  
• Cryptococcosis, extrapulmonary (including meningitis)  
• Disseminated nontuberculosis Mycobacteria infection  
• Progressive multifocal leukoencephalopathy  
• Candida of the trachea, bronchi, or lungs  
• Chronic cryptosporidiosis (with diarrhea)  
• Chronic isosporiasis  
• Disseminated mycosis (eg, histoplasmosis, coccidioidomycosis, penicilliosis)  
• Recurrent nontyphoidal Salmonella bacteremia  
• Lymphoma (cerebral or B-cell non-Hodgkin)  
• Invasive cervical carcinoma  
• Atypical disseminated leishmaniasis  
• Symptomatic HIV-associated nephropathy  
• Symptomatic HIV-associated cardiomyopathy  
• Reactivation of American trypanosomiasis (meningoencephalitis or myocarditis) 
 
 
 
1.2 Oral and oropharyngeal manifestations of HIV 
The oral cavity is one of the most common sites of HIV infection and may be the initial 
site of symptoms and signs.  Oral manifestations of HIV include adenotonsillar 
hypertrophy, oral candidiasis, angular cheilitis, oral hairy leukoplakia, Kaposi sarcoma, 
herpes virus and non-Hodgkins lymphoma.  The otorhinolaryngological abnormalities in 
HIV patients have been reported, but the literature is lacking a description of their 
occurrence during the earlier stages of the HIV infection.  A study presented at the 
international AIDS conference in 1992 reported that out of 210 asymptomatic patients 
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only 16% had a normal ENT examinations, 27% had palpable neck nodes (greater than 
1, less than 3 cm), 7% neck mass (greater than 3 cm), 43% nasopharyngeal lymphatic 
tissue hyperplasia (particularly during earlier stages), 8% extranodal non-Hodgkin's 
lymphomas, 7% Kaposi's sarcoma, 18% oral hairy leukoplakia, 22% oral/pharyngeal 
candidiasis, 2% benign lymphoepithelial cyst of the parotid gland [13].  However there 
was no mention of peritonsillar abscess or deep neck space infections related to HIV.  
 
Based on standard classification and diagnostic criteria, common HIV-associated oral 
disorders can be broadly classified into four categories by pathophysiological process:        
infection (fungal, viral, bacterial), neoplasm, immune-mediated, and other (xerostomia, 
pain syndromes, and nutritional) [14], [table 1.4] 
 
Table 1.4 Classifications of Oral Manifestations of HIV 
 
 
 11
No particular oral lesion is uniquely associated with HIV infection. However, the 
presence of one or more lesions requires that HIV infection be considered as a possible 
underlying cause. Some oral lesions, such as oral candidiasis and oral hairy leukoplakia, 
are so strongly associated with HIV infection that they have been incorporated into the 
Centers for Disease Control and Prevention clinical classification of HIV disease [11]. 
Indeed, the emergence of one or more oral lesions correlates highly with HIV 
progression. A CD4 lymphocyte count of less than 200/mm3 is a reliable prognosticator 
of active disease and probability of shortened lifespan [15–17]. The spectrum of HIV 
associated oral lesions also varies with transmission risk-factor, gender, age, and health-
care access. 
 
1.2.1 Fungal Infections 
The most common HIV-related oral lesion is candidiasis, predominantly due to Candida 
albicans. While Candida can be isolated from 30–50% of the oral cavities of healthy 
adults, making it a constituent of the normal oral flora, clinical oral candidiasis rarely 
occurs in healthy patients [18, 19]. In stark contrast, clinical oral candidiasis has been 
reported to occur in 17–43% of patients with HIV infection and in more than 90% of 
patients with AIDS [20–22]. One report found that unexplained oral candidiasis in healthy 
adults with risk factors for HIV infection predicted the development of clinical signs of 
AIDS within 3 months [23]. 
 
Based on clinical appearance, oral candidiasis can appear as one of four distinct clinical 
entities: erythematous or atrophic candidiasis, pseudomembranous candidiasis, 
hyperplastic or chronic candidiasis, and angular cheilitis. In all cases, the infection is 
superficial.  While in most instances the clinical appearance is adequate to arrive at a 
diagnosis, simple exfoliative cytology will identify the characteristic budding yeast and 
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hyphae when the clinical diagnosis is uncertain.  The appearance of each clinical type of 
candidiasis is summarized in Table 1.5.   Treatment of oral candidiasis is determined by 
the clinical type, distribution, and severity of infection [24].  
 
Table 1.5 Clinical types of Candidiasis  
 
 
 
Unlike the superficial infection of candidiasis, several systemic fungal infections can 
infrequently lead to single or multiple, deep oral lesions with the potential for 
considerable local tissue destruction. Cryptococcosis, histoplasmosis, aspergillosis, and 
mucormycosis are uncommon oral deep fungal infections which require histological 
diagnosis. Treatment typically requires the use of intravenous antifungal therapy with 
amphotericin.  
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1.2.2 Viral Infections 
 
Herpes virus accounts for the majority of HIV-related oral viral infections, most frequently 
as recurrent oral herpes due to herpes simplex virus (HSV) or Epstein-Barr virus (EBV)-
induced oral hairy leukoplakia (OHL) [25]. Less commonly occurring viral infections 
involving the oral cavity include cytomegalovirus and human papilloma virus. 
 
Intraoral herpes in healthy individuals results in multiple, small, shallow ulcerations with 
irregular raised white borders. Small clusters of lesions usually coalesce to form a larger 
ulcer, which heals uneventfully in 7–10 days. While the prevalence of seropositive HSV 
and the rate of reactivation is similar among both HIV-infected and non-infected 
populations, estimated to be 60% for those older than 30 years of age, recurrent intra-
oral HSV in patients with HIV infection often results in ulceration and pain of longer 
duration [26-27]. Recurrent intra-oral HSV lesions occur more commonly on poorly 
keratinized tissue like the buccal and labial mucosa, an uncommon site in healthy 
individuals [28]. 
 
Although Oral Hairy Leukoplakia (OHL) was originally postulated to be pathognomonic 
for HIV infection [29], this lesion has subsequently been reported in other immune 
deficiency states as well as in immunocompetent individuals [30, 31]. It appears as an 
asymptomatic adherent white patch with vertical corrugations, most commonly on the 
lateral borders of the tongue.  It may infrequently be confused with hypertrophic 
candidiasis and is predominantly found in homosexual males.  
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Oral hairy leukoplakia has since been shown to be associated with a localized Epstein-
Barr virus (EBV) infection and occurs most commonly in individuals whose CD4 
lymphocyte count is less than 200/mm3 [17]. While the diagnosis is most often clinical, 
histological inspection will reveal typical epithelial hyperplasia suggestive of EBV 
infection. This asymptomatic lesion does not require treatment. However, for cosmetic 
purposes, some patients may request treatment. Oral acyclovir (3,200 mg daily in 
divided doses), topical podophyllum resin, retinoids, and surgical removal have all been 
reported as successful treatments. In most cases, the lesion returns after initial therapy, 
thus requiring prophylactic treatment with acyclovir 200 mg daily [32-34]. 
 
 
1.2.3 Bacterial infections 
 
Although isolated cases of oral infection with Klebsiella pneumoniae, Enterobacter 
cloacae, Actinomyces israelii, Escherichia coli, and Mycobacterium avium intracellulare 
have been reported in patients with HIV infection, the most common oral lesions 
associated with bacterial infection are linear erythematous gingivitis, necrotizing 
ulcerative periodontitis, and much less commonly, bacillary epithelioid angiomatosis and 
syphilis. In the case of the periodontal infections, the bacterial flora is no different from 
that of a healthy individual with periodontal disease. Thus, the clinical lesion is a 
manifestation of the altered immune response to the pathogens [35]. 
 
While the prevalence of syphilis infection has risen significantly over the past decade, it 
is an uncommon cause of intraoral ulceration, even in HIV infection. Its appearance is no 
different from that observed in healthy individuals; it is a chronic, non-healing, deep, 
solitary ulceration; often clinically indistinguishable from that due to tuberculosis, deep 
fungal infection, or malignancy. Dark field examination may demonstrate treponema. 
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Positive reactive plasma reagin (RPR) and histological demonstration of Treponema 
pallidum is diagnostic. Patients with newly diagnosed syphilis should be referred to their 
physicians for evaluation and treatment; combination treatment with penicillin, 
erythromycin and tetracycline is the treatment of choice, the dosage and duration of 
treatment depending on presence or absence of neurosyphilis [35]. 
 
 
1.2.4 Neoplasms 
 
Kaposi’s sarcoma (KS) is the most common intraoral malignancy associated with HIV 
infection.  Recognition of the lesion is essential, since oral KS is often the first 
manifestation of the disease and is a diagnostic criterion for AIDS [11]. The lesion may 
appear as a red-purple macule, an ulcer, as a nodule or mass. Intraoral KS occurs on 
the heavily keratinized mucosa, the palate being the site in more than 90% of reported 
cases.  However, lesions have also been reported on the gingivae, tongue, and buccal 
mucosa. The skin should also be examined for lesions whenever oral lesions are 
discovered. KS is especially common among homosexual and bisexual males and is 
rarely found in HIV-infected women [36-38]. 
 
 A new human herpes virus (HHV8) has recently been demonstrated to be an important 
cofactor in the development of KS, and prophylaxis with foscarnet and ganciclovir, but 
not acyclovir, has been shown to reduce the incidence of KS in a large at-risk  
cohort [39, 40].  Definitive diagnosis of KS requires histological examination.  
 
There is no cure for KS. Therapy for intraoral KS should be instituted at the earliest sign 
of the lesion, the goal being local control of the size and number of lesions. When only 
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one or a few lesions exist and the lesions are small (<1 cm), intralesional chemotherapy 
is effective. Radiation therapy (800–2,000 cGy) is effective for larger or multiple lesions. 
 
Non Hodgkins Lymphoma is the most common lymphoma associated with HIV infection 
and is usually seen in late stages with CD4 lymphocyte counts of less than 100/mm3. It 
appears as a rapidly enlarging mass, less commonly as an ulcer or plaque, and most 
commonly on the palate or gingivae. NHL may be indistinguishable from masses caused 
by KS or other diseases in HIV-infected patients. Histological examination is essential for 
diagnosis and staging. Prognosis is poor, with mean survival time of less than one year, 
despite treatment with multi-drug chemotherapy [41]. 
 
 
 
1.3     Peritonsillar Abscess  
 
 
1.3.1 Prevalence and Etiology 
Peritonsillar abscess most commonly occurs in adult patients during November to 
December and April to May, which coincides with the highest incidence rates of 
streptococcal pharyngitis and exudative tonsillitis [42].  Peritonsillar abscess has 
traditionally been regarded as the end point of a continuum that begins as acute 
exudative tonsillitis, progresses to cellulitis, and eventually forms an abscess. 
 
A recent review implicates Weber’s glands as playing a key role in the formation of 
peritonsillar abscesses [43, 44].  This group of 20 to 25 mucous salivary glands are 
located in the space just superior to the tonsil in the soft palate and are connected to the 
surface of the tonsil by a duct [44].  The glands clear the tonsillar area of debris and 
 17
assist with the digestion of food particles trapped in the tonsillar crypts.  If Weber’s 
glands become inflamed, local cellulitis can develop.  As the infection progresses, the 
duct to the surface of the tonsil becomes progressively more obstructed from 
surrounding inflammation. The resulting tissue necrosis and and pus formation produce 
the classic signs and symptoms of peritonsillar abscess [45].   
 
These abscesses generally form in the area of the soft palate, just above the superior 
pole of the tonsil, in the location of Weber’s glands.  The occurrence of peritonsillar 
abscesses in patients who have undergone tonsillectomy further supports the theory that 
Weber’s glands have a role in the pathogenesis. Other clinical variables include 
significant periodontal disease and smoking [43]. 
 
A peritonsillar abscess is a polymicrobial infection, but Group A streptococcus is the 
predominate organism [43].  Common organisms associated with peritonsillar abscess 
are shown in table 1.6 
 
Table 1.6 Common organisms 
 
 
 
 
 
 
 18
1.3.2 Relevant Anatomy 
The palatine tonsils are paired lymphoid organs found between the palatoglossal and 
palatopharyngeal folds of the oropharynx.  They are surrounded by a thin capsule that 
separates the tonsil from the superior and middle constrictor muscles.  The anterior and 
posterior pillars form the front and back limits of the peritonsillar space.  Superiorly, this 
potential space is related to the torus tubarius, while inferiorly it is bounded by the 
pyriform sinus [44].   
Composed solely of loose connective tissue, a severe infection may rapidly result in pus 
formation.  The inflammation and suppurative process may extend to involve the soft 
palate, the lateral wall of the pharynx, and, occasionally, the base of the tongue.  The 
tonsillar fossa has a rich network of lymphatic vessels leading to the parapharyngeal 
space and the upper cervical lymph nodes, which explains the pattern of adenopathy 
observed clinically.  Ipsilateral upper cervical lymphadenopathy is the result of the 
spread of infection to the regional lymphatics.  Occasionally, the severity of the 
suppurative process may lead to a cervical abscess, especially in very fulminant or 
rapidly progressive cases [43, 44].   
The tonsils form during the last months of gestation and grow irregularly, reaching their 
largest size at approximately six or seven years of age. The tonsils begin to gradually 
involute at puberty, and by older age little tonsillar tissue remains [46].  When healthy, 
the tonsils do not project beyond the tonsillar pillars medially [47].   
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1.3.3 Clinical Manifestations 
Patients with peritonsillar abscess appear ill and present with fever, malaise, sore throat, 
dysphagia, or otalgia. The throat pain is markedly more severe on the affected side and 
is often referred to the ear on the same side. Physical examination usually reveals 
varying degrees of trismus, with the patient having difficulty opening his or her mouth 
because of pain from inflammation and spasm of masticator muscles [43].  Swallowing is 
also highly painful, resulting in pooling of saliva or drooling [48].  Patients often speak in 
a muffled voice (also called “hot potato voice”).  
 
Markedly tender cervical lymphadenitis may be palpated on the affected side. Inspection 
of the oropharynx reveals tense swelling and erythema of the anterior tonsillar pillar and 
the soft palate overlying the infected tonsil. The tonsil is generally displaced inferiorly 
and medially with contralateral deviation of the uvula. 
 
 
1.3.4 Diagnosis 
The diagnosis of peritonsillar abscess is often made on the basis of a thorough history 
and physical examination. Differential diagnosis includes infectious mononucleosis, 
lymphoma, peritonsillar cellulitis, and retromolar or retropharyngeal abscess. Patients 
often present with peritonsillar cellulitis with the potential to progress to abscess 
formation. In peritonsillar cellulitis, the area between the tonsil and its capsule is 
oedematous and erythematous, but pus has not yet formed [5].   
 
On occasions when the diagnosis of peritonsillar abscess is in question, the presence of 
pus on needle aspiration or radiological testing may help confirm the diagnosis. Trans-
cutaneous or intraoral ultrasonography also can be helpful in identifying an abscess and 
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in distinguishing peritonsillar abscess from peritonsillar cellulites [5, 43].  If spread of the 
infection beyond the peritonsillar space or complications involving the lateral neck space 
are suspected, computed tomography (CT) or magnetic resonance imaging (MRI) is 
indicated. 
 
 
1.3.5 Management 
Drainage of the abscess, antibiotics, and supportive therapy to maintain hydration and 
pain control are the foundation of treatment for peritonsillar abscess.  The main 
procedures for the drainage of peritonsillar abscess are needle aspiration, incision and 
drainage, and immediate tonsillectomy.  
 
Drainage using any of these methods combined with antibiotic therapy will result in 
resolution of the peritonsillar abscess in more than 90 percent of cases [43].  The acute 
surgical management of peritonsillar abscess has evolved over time from routine 
immediate tonsillectomy to increased use of incision and drainage or needle aspiration 
[49].  Immediate abscess tonsillectomy has not been proven to be any more effective 
than needle aspiration or incision and drainage, and it is considered to be less cost-
effective [50].  Several studies comparing needle aspiration with incision and drainage 
have found no significant statistical differences in outcomes [49, 50]. 
 
Although it is not routinely performed for the treatment of peritonsillar abscess, 
immediate tonsillectomy should be considered for patients who have strong indications 
for tonsillectomy, including those who have symptoms of sleep apnoea, a history of 
recurrent tonsillitis (four or more infections per year despite adequate medical therapy), 
or a recurrent or nonresolving peritonsillar abscess[43].  Initial empiric antibiotic therapy 
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should include antimicrobials effective against Group A streptococcus and oral 
anaerobes [51].   
 
Several studies have shown intravenous penicillin alone to be as clinically effective as 
broader-spectrum antibiotics, provided the abscess has been adequately drained 
[50,52].  In these studies, inadequate clinical response following 24 hours of antibiotic 
therapy played a significant role in the decision to use broad-spectrum antibiotics. 
Several other studies have reported that more than 50 percent of culture results 
demonstrated the presence of beta-lactamase producing anaerobes, leading many 
physicians to use broader-spectrum antibiotics as first-line therapy [45, 52].  
 
 
1.3.6 Complications 
Potential complications of peritonsillar abscess include extension into deep spaces in the 
neck (parapharyngeal abscess), airway obstruction, aspiration, or haemorrhage from 
erosion or septic necrosis into the carotid sheath [43].  See table 1.7 
 
Table 1.7 Complications of Peritonsillar Abscess 
 
 
 
 
 
 22
CHAPTER 2 - MATERIALS AND METHODS 
 
 
 
2.0 Justification of the Study 
There has been only one documented study describing the relationship between 
peritonsillar abscess and the HIV status of patients (1995).  Conclusions drawn from this 
study revealed a HIV positive rate of 18% in patients with peritonsillar abscess, higher 
than the adult prevalence rate of 17.6 % from Statsistics South Africa 2008, coupled with 
the absence of HIV symptoms [53].  Due to the high incidence of head and neck 
manifestations in HIV positive patients identifying a clinical marker (quinsy) in the earlier 
stages of HIV infection would allow for better screening, earlier diagnosis and treatment 
of HIV infection.  
 
 
2.1       Purpose of the Study 
Hypothesis:  “The clinical characteristics and/or management of peritonsillar 
                        abscess will be affected by the HIV status of patients ”   
 
2.1.1 Aim 
The overall aim of this project was to assess the relationship between peritonsillar 
abscess and the HIV status of patients admitted to the adult ENT wards at the Chris 
Hani Baragwanath Hospital. 
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2.1.2 Specific Objectives 
1. Determine the prevalence of HIV in patients with peritonsillar abscess. 
2. Describe:    
§ Demographic details of HIV positive patients with peritonsillar abscess with  
regards to age, gender and race 
§  Presenting clinical features of peritonsillar abscess which include 
- Pyrexia 
- Trismus 
- Site of Peritonsillar swelling (unilateral/bilateral) 
- Lymphadenopathy 
- Pus aspirated and if incision and drainage performed 
§ Associated oral and oropharyngeal manifestations of HIV (candida, angular 
cheilitis, oral hairy leukoplakia, Kaposi’s sarcoma and lymphoma) in patients 
with peritonsillar abscess 
§ Laboratory features, including  
  - HIV Rapid and Elisa 
§ Determine if HIV affects the length of treatment, complications and hospital 
stay in patients with peritonsillar abcsess 
 
 
2.2 Study Design 
This was an analytical cross sectional study utilising retrospective clinical data.  This 
involved analysis of retrospective data from ward registers, patient records, treatment 
registers and National Health Laboratory System (NHLS) databases.  
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2.3 Study Setting 
The study was conducted in the adult ENT ward at the Chris Hani Baragwanath 
Hospital.  Being primarily based at this hospital as an ENT registrar and aware of the 
record keeping and protocols for admission and management, I opted to use this study 
sample.  This hospital, with its 2 888 beds, is the largest acute care hospital in the world. 
It is situated to the south west of Johannesburg, on the southern border of Soweto. The 
Hospital grounds cover an area of 173 acres, consisting of 429 buildings with a total floor 
area of 233 785 m².  The hospital has a staff establishment of nearly 5000, 600 are 
doctors and 2 000 are nurses.  It is the only public hospital serving ±3, 5 million people in 
Soweto and provides half of all the hospital services in Southern and Western Gauteng 
[7].  The study sample consisted of patient records over a 4 year period from January 
2005 to December 2008. The study population included all patients admitted to the ENT 
ward with peritonsillar abscess who have been tested for HIV.   
 
 
2.4 Data Collection 
Patients included in this study were identified by using the ward register to search for the 
discharge diagnosis (Peritonsillar abscess/ Quinsy).  The Patient name and hospital 
number were obtained and records retrieved from records department.  Laboratory 
information (HIV rapid/elisa) was accessed via data recorded in the NHLS database.  
Data collection sheets were utilized for the record reviews [Figure 2.1].   
 
The following data was extracted from patient records onto the data capture sheet  
§ HIV status and peritonsillar abscess by gender, age and race  
§ Clinical presentation including oral manifestations of HIV (candida, angular 
cheilitis, oral hairy leukoplakia, Kaposi sarcoma and lymphoma and other) 
§ Number of days admitted 
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§ Antibiotics used 
§ Aspiration and/or Incision and Drainage 
§ Complications 
 
 
Figure 2.1 DATA COLLECTION SHEET 
 
 
Patient Identity No.          1        2       3        4        5         6 
Demographic 
details 
Age       
Gender       
Race       
Clinical 
presentation 
of  Quinsy 
Temp( Pyrexial) Y N Y N Y N Y N Y N Y N 
Trismus Y N Y N Y N Y N Y N Y N 
Aspirate Y N Y N Y N Y N Y N Y N 
LN Y N Y N Y N Y N Y N Y N 
Site L R B L R B L R B L R B L R B L R B 
Oral 
manifestation 
of HIV 
Candida Y N Y N Y N Y N Y N Y N 
Angular Cheilitis Y N Y N Y N Y N Y N Y N 
Hairy Leukoplakia Y N Y N Y N Y N Y N Y N 
Kaposi Y N Y N Y N Y N Y N Y N 
Lymphoma Y N Y N Y N Y N Y N Y N 
Other       
Laboratory HIV (Rapid/Elisa)       
Management Days Admitted       
Antibiotics used       
Aspiration Y N Y N Y N Y N Y N Y N 
Incision+Drainage Y N Y N Y N Y N Y N Y N 
Complications       
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2.5 Inclusion and Exclusion Criteria 
All patients admitted to the ENT ward with the diagnosis of peritonsillar abscess during 
the 4 year period were reviewed.   In this study period 450 patient files were reviewed of 
which 291 fulfilled the inclusion criteria.   There were 3 exclusion criteria:  
§ Incomplete or lost Files, 54 patients 
§ Not tested for HIV or Refused HIV testing, 84 patients 
§ Not confirmed Peritonsillar abscess (negative aspirate), 21 patients 
 
 
2.6 Data Analysis 
Numerical data from the records reviewed were coded and captured onto Excel 
spreadsheets and transferred to STATA-10 software for analysis by computer. To 
protect the integrity of the database, I wrote-protected the Excel data and stored it in two 
safe places (CD-ROM and dedicated memory stick) and then only worked with copies. 
 
Descriptive statistics (proportions) were employed to summarize the data. Measures of 
spread, central tendency and association will be calculated.  The analytical tests that 
were used to determine associations are chi square test for categorical variables, and 
unpaired ‘t’ test when two groups of continuous data will be compared. Differences will 
be considered statistically significant if the ‘p’ value is less than 0.05. 
 
 
 
 
 
 27
2.7 Limitations 
§ Retrospective Study – Rely on existing primary data of which the 
quality and consistency of the patient records may vary. 
§ Loss of patient records thereby excluding them from the study 
§ Study performed only at one institute (not multicentre study).  The 
results may not be generalizable to other districts or provinces in the 
country. 
 
 
2.8 Ethical and Legal Considerations 
This study was approved by the Ethics Committee (medical) of the University of the 
Witwatersrand (clearance no. MP090638).   Permission has been granted from the CEO 
of Chris Hani Baragwanath Hospital, National Health Laboratory Services and the Head 
of ENT Department to access patient files and laboratory results for the purpose of 
completing this Mmed research report.  
 
This was a retrospective study in which all patient information and data were accessed 
from existing records.  All HIV results on patients included in this study have been tested 
as per ward protocols which included pre and post test counselling, as well as referral for 
further management and follow up. 
 
Data analyzed did not include patient names or hospital numbers but had patient 
identifiers which were only known to the researcher and all records and documentation 
housed securely.  Electronic records were maintained in password protected computers.   
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CHAPTER 3 – RESULTS 
 
 
3.1 Sample studied 
In this study period 450 patient files were reviewed of which 291 (64.7%) fulfilled the 
inclusion criteria.  One hundred and fifty nine patients were excluded from the study due 
incomplete or lost files, not tested for HIV and no confirmed peritonsillar abscess.  The 
age ranged from 15 to 63 years with a mean (SD) 29.3 years (9.58).  From the 291 
patients, 86 (29.55%) were HIV positive.     
  
3.2 Demographic Data 
 
3.2.1 Gender 
The study sample consisted of 164 females (56.36%) and 127 males (43.64%) with a 
female to male ratio of 1.29 to 1.  Among the 86 HIV positive patients, 52 were female 
and 34 male, with a gender ratio of 1.53F: 1M [Table 3.1, Figure 3.1].  No statistical 
difference in HIV status was noted. 
 
Table 3.1 :HIV status by gender   Figure 3.1 :HIV Status by Gender  
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Negative
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                 P- value = 0.360 
HIV Female Male Total 
Negative 112 93 205 
Positive 52 34 86 
Total 164 127 291 
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3.2.2 Age 
The age ranged from 15 to 63 years with a mean (SD) 29.3 years (9.58).  From the 86 
HIV positive patients, the age group 30-34 showed the highest HIV positive rate of 
27.9% [Table 3.2, Figure 3.2]. Two-sample t test revealed a mean (SD) age of 28.7years 
(9.67) in the HIV negative group and a mean (SD) age of 30.89years (9.58) in the HIV 
positive group. No statistical significance was noted (P=0.0815). 
  
Table 3.2 : HIV positive % by Age Group 
Age Group (Years) % HIV Positive 
15-19         15.1 
20-24           8.1 
25-29         13.9 
          30-34         27.9 
          35-39         23.2 
        >40       11.6 
 
 
Figure 3.2 : HIV positive % by Age Group      
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3.2.3 Race 
Two hundred and thirty-six patients (81.1%) were Black, of whom 74 (31.36%) were HIV 
positive.  The Coloured patients had a 20% HIV positive rate, whilst from the 9 Indian 
patients admitted 3 were positive (33.33%).  The White patient population had a HIV 
positive rate of 18.18% [Table 3.3, Figure 3.3].   
 
Table 3.3 :  HIV Status by Race 
          HIV Black Coloured Indian White Total 
Negative  162     28     6      9   205 
Positive    74       7     3      2     86 
Total  236     35     9     11   291 
 
P- value = 0.449 
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     Figure 3.3:         HIV Status by Race 
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3.3 Clinical Features of peritonsillar abscess 
 
3.3.1 Temperature 
The temperature ranged from 36˚C to 39.5˚C.  From the 291 patients a mean (SD) 
temperature of 37.77˚C (2.32˚C) was noted. The t- test revealed no statistical difference 
(P=0.2056).  
 
3.3.2 Trismus    
Two hundred and eighteen patients (74.9%) presented with trismus of which 69 
(31.65%) were HIV positive [table 3.4].  From the clinical notes trismus was not 
adequately graded but its presence clearly documented.  There was no Statistical 
significance noted (P=0.217). 
 
 
Table 3.4 : HIV status by Trismus 
       HIV Status      No Trismus   Trismus          Total 
Negative 54 149 203 
Positive 19   69   88 
Total 73 218 291 
 
P- value = 0.217 
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3.3.3 Site of  Abscess   
One hundred and forty-six patients (50.17%) presented with a left sided peritonsillar 
abscess.  Seven patients presented with bilateral abscess of which 4 were HIV positive 
[Table 3.5, Figure 3.4].   
 
Table 3.5 : HIV status by Site 
       HIV Status      Left   Right Bilateral   Total        
Negative 102 100         3        205 
Positive   44 138         4          86 
Total 146 218         7        291 
 
Fisher’s Exact   P- value = 0.240 
 
Figure 3.4  HIV status by Site  
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3.3.4 Lymphadenopathy   
Forty-nine of patients (16.84%) presented with cervical lymphadenopathy of whom 17 
(34.69%) were HIV negative.  Thirty-two HIV positive patients (37.21%) had cervical 
lymphnodes.  There was no mention of generalized lymphadenopathy in the clinical 
notes.  A statistical significance was noted with a P value of < 0.001, [table 3.6].  
 
Table 3.6 : HIV status by Cervical Lymphnodes  
       HIV Status      Not palpable   Palpable   Total        
Negative 188   17        205 
Positive   54   32          86 
Total 242   49        291 
 
P- value <0.001 
 
 
 
3.4 Oral Manifestations of HIV 
3.4.1 Oral Candida   
Candida was noted in 13 patients (4.47%), all of which were HIV positive shown in  
[table 3.7].  This is statistically significant with a Fisher’s exact P-value < 0.001. 
 
Table 3.7 : HIV status by presence of Candida  
       HIV Status      No Candida   Candida   Total        
Negative 205     0        205 
Positive   73   13          86 
Total 278   13        291 
 
Fisher’s Exact   P- value <0.001 
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3.4.2 Oral  Hairy leukoplakia (OHL) 
Only 2 patients (0.69%) presented with oral hairy leukoplakia and were in the HIV 
positive group shown in table 3.8.  This is statistically not significant with a Fisher’s exact  
P-value =0.087. 
 
Table 3.8 : HIV status by OHL 
       HIV Status      No OHL   OHL    Total        
Negative 205     0        205 
Positive   84     2          86 
Total 289     2        291 
 
Fisher’s Exact   P- value =0.087 
 
3.4.3 Lymphoma 
Six patients (2.06%) presented with lymphoma which was diagnosed by performing 
tonsillectomy biopsy.  The average hospital stay for these patients was 14 days and all 
were HIV positive [table 3.9].  Statistically significance was shown with P-value <0.001. 
 
Table 3.9 : HIV status by Lymphoma 
       HIV Status      No Lymphoma   Lymphoma   Total        
Negative 205     0        205 
Positive   80     6          86 
Total 285     6        291 
 
P- value <0.001 
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3.4.4 Kaposi’s Sarcoma 
Only 1 patient (0.34%) presented with palatal Kaposi’s sarcoma which was biopsied.  
This patient also presented with pulmonary Tuberculosis.  This is statistically not 
significant with a Fisher’s exact P-value =0.296. 
 
Table 3.10 : HIV status by Kaposi’s Sarcoma 
       HIV Status      No Kaposi’s   Kaposi’s    Total        
Negative 205     0        205 
Positive   85     1          86 
Total 290     1        291 
 
Fisher’s Exact   P- value =0.296 
 
 
 
3.4.5 Angular Chelitis  
From the 291 patients in this study none presented with angular chelitis. 
 
3.4.6 Other HIV manifestations 
Two of the HIV positive patients who presented with peritonsillar abscess also had 
pulmonary tuberculosis. Both patients had oral Candida with one of these also having 
Kaposi’s sarcoma.  
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3.5 Laboratory Data 
 
 
3.5.1 HIV Results (Rapid/ Elisa) 
In this study sample 86 (29.55%) patients were HIV positive [Table 3.11, Figure 3.5].   
 
Table 3.11 : Tabulation of HIV Status 
       HIV Status      No. of Patients           % 
Negative 205       70.45 
Positive   86       29.55 
Total 291        100     
 
 
 
Figure 3.5 HIV Status 
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3.6 Management 
 
 
3.6.1 Incision and Drainage 
Aspiration of peritonsillar abscess is part of the inclusion criteria (confirming the 
presence of pus).  From the 291 patients 230 (79.04%) had incision and drainage 
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performed.  Eight of these patients required a repeated incision and drainage and 4 
developed a parapharyngeal abscess which required an incision and drainage in theatre.  
Seventy-two patients (31.30%) were HIV positive shown in Figure 3.6.  There was no 
statistical significant noted.    
 
Figure 3.6 HIV status by Incision And Drainage   
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P- value = 0.204 
 
 
 
 
3.6.2 Antibiotics  
Two hundred and forty-two patients (83.16%) were treated with Augmentin.  There were 
24 patients (8.25%) who required the addition of a second antibiotic (Flagyl), of which 12 
were HIV positive (P-value = 0.039).  Two of these patients also had pulmonary TB and 
were started on Rifafour.  Twenty-two patients were treated with Pen G while 3 patients 
with penicillin allergies were given Erythomycin.  Table 3.12 and Figure 3.7 shows the 
relationship between HIV status and antibiotic use.  
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Table 3.12 HIV Status by Antibiotics  
       HIV Status Augmentin Add Flagyl Pen G Erythro     Total       
Negative       172       12    18      3        205 
Positive         70       12      4      0          86 
Total       242       24    22      3        291 
 
    P- value =0.039 
 
 
Figure 3.7 HIV status by Antibiotics 
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3.6.3 Tonsillectomy 
There were 6 HIV positive patients who underwent tonsillectomy- biopsy which 
confirmed lymphoma.  Only 1 patient had a quinsy- tonsillectomy and was HIV negative. 
 
3.6.4 Complications 
Four patients developed a parapharyngeal abscess and were taken to theatre for 
incision and drainage.  Three were HIV positive and 1 of these patients required a 
tracheotomy for airway compromise.   
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3.6.5 Number of Days Admitted 
The admission length ranged from 1 to 17 days with a mean (SD) 2.65 (2.35) days.  
From the 86 HIV positive patients, the mean length of hospital stay was 3.80 days with a 
standard deviation of 3.72 days.  [Figure 3.8]. Two-sample t test revealed a statistical 
significance with a P-value of <0.001. 
 
 
Figure 3.8  HIV Status by Days admitted 
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   P-Value < 0.001 
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CHAPTER 4– DISCUSSION 
 
 
 
The overall aim of this project was to assess the relationship between peritonsillar 
abscess and the HIV status of patients with regards to demographic details, presenting 
clinical features, oral manifestations of HIV and management. 
 
 
4.1 Sample Collection 
 
In considering the findings of this study it is important to bear in mind the following 
limitations.  Being a retrospective study I relied on existing primary data of which the 
quality and consistency of the patient records varied.   
 
This study was conducted at Chris Hani Baragwanath Hospital which serves a 
population of ±3,5 million people in Soweto and provides half of all the hospital services 
in Southern and Western Gauteng [7].  Due to this large number of patients being 
admitted on a daily basis, accessing filed records proved to be a major challenge.  From 
the 450 patient files reviewed 54 (12%) were incomplete or lost and 84 patients (18.6%) 
were not tested for HIV and subsequently excluded.  Thus the absolute presentation rate 
of peritonsillar abscess at this hospital is inaccurate.  
 
Another limitation of note is that this study was performed at only one institute (not 
multicentre study).  The results may not be generalizable to other districts or provinces in 
this country.  Two hundred and ninty-one patients fulfilled the inclusion criteria. 
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4.2 HIV Prevalence in Peritonsillar Abscess 
 
HIV and AIDS is one of the major challenges facing South Africa today.  The national 
HIV prevalence rates have been stable for several years and there is now evidence of 
the epidemic being on the decline.  From the 291 patients included in this study, 86 
(29.55%) were HIV positive.  This is significantly higher than the adult (15-49years) HIV 
prevalence rate of 17.64% [6]. 
 
 
4.3 Demographic Data 
There was no statistical significance for the demographic data reviewed; however there 
are some trends that need further discussion. 
 
4.3.1 Gender 
The study sample consisted of 164 females (56.36%) and 127 males (43.64%) with a 
female to male ratio of 1.29 to 1.  Among the 86 HIV positive patients, 52 were female 
and 34 male, with a gender ratio of 1.53F: 1M.  This is in keeping with the South African 
adult HIV prevalence gender ratio of 1.55F:1M [2] 
 
4.3.2 Age 
In this study the mean age of presentation of peritonsillar abscess was 29.3 years.  The 
age groups 30-34 and 35-39 years showed the highest HIV positive rates of 27.9% and 
23.2% respectively. This is confirmed when compared with the South African antenatal 
HIV survey of 2007 where there was a significant increase in these specific age groups, 
from 2006 to 2007 with the age group 30-34 being the highest with 40.2%.  The decline 
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in the age group (15-19years) particularly, implies a reduction in new infections 
(incidence) in the general population [6]. 
 
 
4.3.3 Race 
Two hundred and thirty-six patients (81.1%) were black, of which 31.36% were HIV 
positive.  The large number of black patients can be explained by the fact that Chris Hani 
Baragwanath Hospital falls in a region with a higher black population. 
 
 
4.4 Clinical Features of peritonsillar abscess 
 
4.4.1 Temperature 
The mean temperature in the HIV positive group was 37.5˚C compared with the HIV 
negative group of 37.8˚C.  There was no statistical significance with HIV status 
 
4.4.2 Trismus 
Trismus was clearly documented in patient files but not adequately graded.  Two 
hundred and eighteen patients (74.9%) presented with trismus of which 69 (31.65%) 
were HIV positive.  No significance was noted. 
 
4.4.3 Site of Abscess 
One hundred and forty-six patients (50.17%) presented with a left sided peritonsillar 
abscess.  Seven patients presented with bilateral abscess of which 4 were HIV positive.  
There was no effect of HIV on the site of the abscess. 
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4.4.4 Lymphadenopathy 
Only the presence of cervical lymphnodes was documented in the clinical notes.  There 
was no mention of generalized lymphadenopathy.  Forty-nine patients (16.84%) 
presented with cervical lymphadenopathy of whom 17 (34.69%) were HIV negative.  
Thirty-two HIV positive patients (37.21%) had cervical lymphnodes.  Analysis revealed a 
statistical significance; however cervical lymphadenopathy is also a common presenting 
sign of peritonsillar abscess. 
 
 
4.5 Oral Manifestations of HIV 
 
4.5.1 Oral Candida 
Candida was noted in 13 patients (4.47%), all of which were HIV positive.  There was a 
statistical significance noted confirming the current literature that candidiasis is a 
common HIV-related oral lesion.  Clinical oral candidiasis has been reported to occur in 
17-43% of patients with HIV infection and in more than 90% of patients with 
 AIDS [20-22].   
 
4.5.2 Oral Hairy Leukoplakia 
Only 2 patients (0.69%) presented with oral hairy leukoplakia and were in the HIV 
positive group. This was not significant.  OHL falls under the clinical stage 3 of the WHO 
classification and is not one of the common early manifestations of HIV.  
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4.5.3 Lymphoma 
The type of lymphoma was not clearly described in the patient records.  Six patients 
(2.06%) presented with lymphoma which was diagnosed by performing tonsillectomy 
biopsy.  The average hospital stay for these patients was 14 days and all were HIV 
positive.  Statistical significance was demonstrated.  Lymphoma associated with HIV 
infection is usually seen in late stages with CD4 lymphocyte counts of less than 
100/mm3 [41].      
 
4.5.4 Kaposi’s Sarcoma 
Only 1 patient (0.34%) presented with palatal Kaposi’s sarcoma which was biopsied.  
This patient also presented with pulmonary Tuberculosis (Advanced stages of HIV).  
Kaposi’s sarcoma is the most common intraoral malignancy associated with HIV 
infection and is a diagnostic criterion for AIDS [11]. 
 
4.5.5 Other HIV manifestations 
Not one patient presented with Angular Chelitis.  Two patients with advanced HIV 
disease who presented with peritonsillar abscess also had pulmonary tuberculosis. Both 
patients had oral Candida with one of these also having Kaposi’s sarcoma.  
 
 
4.6 Management 
Drainage of the abscess, antibiotics, and supportive therapy to maintain hydration and 
pain control are the foundation of treatment for peritonsillar abscess. 
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4.6.1 Incision and Drainage 
The gold standard for diagnosis of peritonsillar abscess remains the collection of pus 
from the abscess through needle aspiration. A positive aspirate was part of the inclusion 
criteria, so all patients had the peritonsillar swelling aspirated.  Two hundred and thirty 
patients (79.04%) had an incision and drainage performed, with 31.3% being HIV 
positive. Eight patients required a repeated incision and drainage and 4 developed a 
parapharyngeal abscess which was taken to theatre for incision and drainage.  There 
was no significance noted. 
 
The main procedures for the drainage of peritonsillar abscess are needle aspiration, 
incision and drainage, and immediate tonsillectomy. Drainage using any of these 
methods combined with antibiotic therapy will result in resolution of the peritonsillar 
abscess in more than 90 percent of cases [43].  The acute surgical management of 
peritonsillar abscess has evolved over time from routine immediate tonsillectomy to 
increased use of incision and drainage or needle aspiration [49].  Immediate abscess 
tonsillectomy has not been proven to be any more effective than needle aspiration or 
incision and drainage, and it is considered to be less cost-effective [50].  Several studies 
comparing needle aspiration with incision and drainage have found no significant 
statistical differences in outcomes [49, 50]. 
 
 
4.6.2 Antibiotics 
Augmentin was the antibiotic of choice with 242 patients (83.16%) treated with this 
antibiotic.  There were 24 patients (8.25%) who required the addition of a second 
antibiotic (Flagyl), of which 12 were HIV positive.  Two of these patients also had 
pulmonary TB and were started on Rifafour.  Twenty-two patients were treated with  
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Pen G while 3 patients with penicillin allergies were given Erythomycin.  There was no 
significant difference with regards to hospital stay and resolution of symptoms in patients 
treated with Pen G or Augmentin. 
 
Several studies have shown intravenous penicillin alone to be as clinically effective as 
broader-spectrum antibiotics, provided the abscess has been adequately drained  
[50, 52].  In these studies, inadequate clinical response following 24 hours of antibiotic 
therapy played a significant role in the decision to use broad-spectrum antibiotics. 
Several other studies have reported that more than 50 percent of culture results 
demonstrated the presence of beta-lactamase producing anaerobes, leading many 
physicians to use broader-spectrum antibiotics as first-line therapy [45, 52]. 
 
 
4.6.3 Tonsillectomy 
Only one Quinsy-tonsillectomy was performed on a 43 year old HIV negative patient for 
potential airway compromise.  Six HIV positive patients underwent tonsillectomy biopsy 
for suspected lymphoma after having a non resolving peritonsillar abscess.  All of which 
were confirmed with lymphoma. 
 
Although it is not routinely performed for the treatment of peritonsillar abscess, 
immediate tonsillectomy should be considered for patients who have strong indications 
for tonsillectomy, including those who have symptoms of sleep apnoea, a history of 
recurrent tonsillitis (four or more infections per year despite adequate medical therapy), 
or a recurrent or nonresolving peritonsillar abscess [43].   
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4.6.4 Complications 
Four patients developed a parapharyngeal abscess of which 3 were HIV positive.  One 
of these patients required a tracheotomy for airway compromise.  This is a relatively low 
complication rate of peritonsillar abscess. 
 
4.6.5 Number of Days Admitted 
The admission length ranged from 1 to 17 days with a mean (SD) 2.65 (2.35) days.  
From the 86 HIV positive patients, the mean length of hospital stay was 3.80 days with a 
standard deviation of 3.72 days.  This was statistically significant with HIV positive 
patients requiring a longer hospital stay.  The bacterial flora within the oral cavity is no 
different from that seen in healthy patients, and thus the altered immune response in HIV 
infection probably results in a higher incidence of adding a second antibiotic and 
increased hospital stay.  Also the increased incidence in Lymphoma and Kaposi’s 
sarcoma in HIV patients may prolong the hospital stay due to the necessity of performing 
biopsies.  
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4.7 Summary 
 
The clinical data reviewed in this study revealed that majority of the patients presenting 
with Peritonsillar abscess were generally healthy and exhibited limited or no signs of HIV 
infection, (WHO clinical stage 1). 
 
From the 291 patients, 86 (29.55%) were HIV positive.  This is significantly higher than 
the adult (15-49years) HIV prevalence rate of 17.64% [6].  The age ranged from 15 to 63 
years with a mean (SD) 29.3 years (9.58).  The age group 30-34 showed the highest 
HIV positive rates of 27.9% which is in keeping with the results of the South African 
antenatal HIV survey of 2007.  There was no difference in the clinical presentation of 
peritonsillar abscess in HIV positive and negative patients.  There was no statistical 
significance in the management of HIV positive patients; however hospital stay was 
longer with a mean of 3.802 days and 1.2 days longer than HIV negative patients.   
 
 
4.8 Suggested further research 
 
There has been only one documented prospective study describing the relationship 
between peritonsillar abscess and the HIV status of patients (1995).  A prospective study 
should be carried out with a multi-centre sample.  A useful addition would be to include 
the CD4 and CD8 counts as well as looking at the microbiology of peritonsillar abscess. 
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4.9 Conclusions 
 
From this study sample the HIV prevalence of 29.55% suggests that peritonsillar 
abscess may be an early clinical marker of HIV infection. Due to the high incidence of 
head and neck manifestations in HIV positive patients identifying a clinical marker 
(quinsy) in the earlier stages of HIV infection would allow for better screening, earlier 
diagnosis and treatment of HIV infection.  
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